NattoPharma strengthening its management team

NattoPharma has today appointed Dr. Leon Schurgers as Vice President R&D and Dr. Elke Theuwissen as Manager Regulating Affairs. Dr. Schurgers is working for the Division on Vitamin K Research. This Division forms an essential part of the Cardiovascular Research Institute CARIM, which is the largest research institute of the University of Maastricht. The work includes molecular biology, biochemistry, animal and human nutrition, pharmacology, and clinical studies in the fields of atherosclerosis and osteoporosis. Leading the scientific part on vitamin K-research and supervising three technical engineers forms Dr. Schurgers major occupation. Additionally, Dr. Schurgers is a member of the American Society of Bone and Mineral Research and the American Heart Association. He is referee for international scientific journals, and has published over 30 research papers, reviews, and book chapters in the international scientific press. Dr. Schurgers is also an Assistant Professor at the Department of Biochemistry, a function he will combine with his work at NattoPharma.
Dr. Theuwissen has been employed by VitaK for the last 2 years managing human and animal studies for NattoPharma. She has also supported NattoPharma in regulatory affairs and written scientific articles for us.
 "NattoPharma has an exclusive partnership agreement with VitaK, where 10 scientists are working for us, and participate strongly in our scientific development program, together with other scientists all over the world. By appointing Dr. Schurgers and Dr. Theuwissen directly in NattoPharma, we have strengthening our in-house expertise on vitamin K and R&D proficiency" says President and CEO Morten Sundstø in NattoPharma".
VitaK BV is an SME closely associated with the CArdioVascular Research Institute Maastricht (CARIM), University of Maastricht, The Netherlands. VitaK was established as a corporate business in March, 2001 and has expanded its expertise to areas outside that of CARIM. VitaK's prime expertise is technology around all forms of vitamin K and vitamin K-dependent proteins. VitaK is involved in discovering new functions for vitamin K, developing food supplements and health food containing new formulations of vitamin K in combination with other vitamins, minerals and trace elements, and in developing new assays to specifically assess the vitamin K status in liver, bone, cartilage and vascular tissue. One aspect of the latter line is diagnostics based on circulating MGP, which is a patented system to monitor cardiovascular disease via biochemical markers in blood.
About NattoPharma
NattoPharma, Norway is the exclusive international supplier of MenaQ7, the natural Vitamin K2. NattoPharma has entered into a multi-year research and development program to substantiate and discover the health benefits of natural vitamin K2 for applications in the exciting marketplace for functional food and health food supplements.
For more information, please visit our website

For more information, please contact:
Mr. Morten Sundstø
+ 47 950 61 860

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.


Documents & Links